General Information of Drug (ID: DMB8MNU)

Drug Name
CHIR-99021 Drug Info
Synonyms CHIR99021; CHIR 99021; CT-99021; CT99021
Indication
Disease Entry ICD 11 Status REF
Allergic inflammation 4A80-4A85 Patented [1]
Graft rejection NE84 Patented [1]
Cross-matching ID
PubChem CID
9956119
ChEBI ID
CHEBI:91091
CAS Number
CAS 252917-06-9
TTD Drug ID
DMB8MNU

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DOT
Drug Status:
Clinical Trial Drug(s)
Patented Agent(s)
Preclinical Drug(s)
Discontinued Drug(s)
Investigative Drug(s)
Approved Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
R-roscovitine DMSH108 Non-small-cell lung cancer 2C25.Y Phase 2 [6]
Ro 31-7453 DM83QCL Solid tumour/cancer 2A00-2F9Z Phase 2 [7]
P276-00 DM9DJL2 Mantle cell lymphoma 2A85.5 Phase 2 [6]
P-276 DMMJUHD Breast cancer 2C60-2C65 Phase 2 [8]
RGB-286638 DMEGOQP Haematological malignancy 2B33.Y Phase 1 [9]
AG-024322 DMY4WVK Solid tumour/cancer 2A00-2F9Z Phase 1 [6]
PHA-793887 DM2Y4FG Solid tumour/cancer 2A00-2F9Z Phase 1 [10]
Oxazolyl methylthiothiazole derivative 1 DMZM6FW N. A. N. A. Patented [11]
PMID25991433-Compound-A1 DM89LF0 N. A. N. A. Patented [12]
KENPAULLONE DMAGVXW Discovery agent N.A. Patented [13]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
BVD-523 DMNB4XK Melanoma 2C30 Phase 2 [14]
HH2710 DM0C5MV Solid tumour/cancer 2A00-2F9Z Phase 1/2 [15]
ASTX029 DMVZXIA Solid tumour/cancer 2A00-2F9Z Phase 1/2 [16]
VAN-10-4-eluting stent DM3ZW6A Artery stenosis BD52 Phase 1 [17]
GDC-0994 DMFC2OY Solid tumour/cancer 2A00-2F9Z Phase 1 [18]
JSI-1187 DMVJWBS Solid tumour/cancer 2A00-2F9Z Phase 1 [19]
LY3214996 DMFDAY7 Solid tumour/cancer 2A00-2F9Z Phase 1 [20]
COR-D DMLXMCB T-cell leukaemia 2A90 Preclinical [21]
SB220025 DMSBUET Arthritis FA20 Terminated [22]
RO-316233 DMAGLPW Discovery agent N.A. Investigative [23]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
AMO-02 DMJRU3A Myotonic dystrophy 8C71.0 Phase 2/3 [24]
LY2090314 DMTBFE4 Acute myeloid leukaemia 2A60 Phase 2 [1]
Lithium DMZ3OU6 Bipolar disorder 6A60 Phase 2 [25]
Tideglusib DME4LA1 Alzheimer disease 8A20 Phase 2 [26]
9-ING-41 DM57TY3 Myelofibrosis 2A20.2 Phase 2 [27]
Neu-120 DMXKOUC Parkinson disease 8A00.0 Phase 1/2 [28]
KENPAULLONE DMAGVXW Discovery agent N.A. Patented [29]
TDZD-8 DMG6Q45 Malignant glioma 2A00.0 Patented [30]
AR-A014418 DMUPN01 Ovarian cancer 2C73 Patented [31]
PMID26161698-Compound-18 DM6JVR5 N. A. N. A. Patented [11]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [32]
LY2090314 DMTBFE4 Acute myeloid leukaemia 2A60 Phase 2 [1]
Lithium DMZ3OU6 Bipolar disorder 6A60 Phase 2 [25]
KENPAULLONE DMAGVXW Discovery agent N.A. Patented [1]
TDZD-8 DMG6Q45 Malignant glioma 2A00.0 Patented [1]
AR-A014418 DMUPN01 Ovarian cancer 2C73 Patented [1]
PMID27828716-Compound-21 DMO1NAR N. A. N. A. Patented [1]
Thiadiazolidindione derivative 2 DM5AUL0 N. A. N. A. Patented [1]
PMID27828716-Compound-18 DMNR6KL N. A. N. A. Patented [1]
PMID27828716-Compound-BIO-acetoxime DMUM5L6 Malignant glioma 2A00.0 Patented [1]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [33]
Gefitinib DM15F0X Colon adenocarcinoma Approved [34]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [35]
Selenium DM25CGV N. A. N. A. Approved [36]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [37]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [38]
Quercetin DM3NC4M Obesity 5B81 Approved [39]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [40]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [41]
Glucosamine DM4ZLFD Osteoarthritis FA00-FA05 Approved [42]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [43]
Methotrexate DM2TEOL Anterior urethra cancer Approved [44]
Quercetin DM3NC4M Obesity 5B81 Approved [45]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [46]
Leflunomide DMR8ONJ Arthritis FA20 Approved [47]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [48]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [49]
Menadione DMSJDTY Vitamin K deficiency 5B59 Approved [43]
Arsenic DMTL2Y1 N. A. N. A. Approved [50]
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [51]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 1A2 (CYP1A2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Zolmitriptan DM1IB4Q Migraine 8A80 Approved [52]
Rofecoxib DM3P5DA Osteoarthritis FA00-FA05 Approved [52]
Etoricoxib DM6A4NW Rheumatoid arthritis FA20 Approved [52]
Capsaicin DMGMF6V Back pain ME84.Z Approved [53]
Hesperetin DMKER83 High blood cholesterol level 5C80.00 Approved [54]
Stiripentol DMMSDOY Dravet syndrome 8A61.11 Approved [55]
Nifedipine DMSVOZT Angina pectoris BA40 Approved [56]
Zileuton DMVRIC2 Allergic asthma CA23.0 Approved [57]
Nicotine DMWX5CO Lung cancer 2C25.0 Approved [58]
Clonidine DM6RZ9Q Attention deficit hyperactivity disorder 6A05.Z Approved [59]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 2E1 (CYP2E1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fomepizole DM6VOWQ Athylene glycol or methanol poisoning NE61 Approved [60]
Ademetionine DMYQDBO Hepatic fibrosis DB93.0 Approved [61]
Theophylline DMRJFN9 Bronchitis CA20 Approved [59]
Rifampicin DM5DSFZ Non-insulin dependent diabetes 5A11 Approved [62]
Ethanol DMDRQZU Chronic pain MG30 Approved [63]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [64]
Phenobarbital DMXZOCG Cluster headache 8A81.0 Approved [65]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [66]
Didanosine DMI2QPE Human immunodeficiency virus infection 1C62 Approved [59]
Thioridazine DM35M8J Schizophrenia 6A20 Approved [67]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Cytochrome P450 3A4 (CYP3A4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Eplerenone DMF0NQR Heart failure BD10-BD13 Approved [68]
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [69]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [70]
Voriconazole DMAOL2S Aspergillosis 1F20 Approved [71]
Proguanil DMBL79I Malaria 1F40-1F45 Approved [72]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [72]
Loratadine DMF3AN7 Allergy 4A80-4A85 Approved [73]
Nelfinavir mesylate DMFX6G8 N. A. N. A. Approved [74]
Capsaicin DMGMF6V Back pain ME84.Z Approved [75]
Axitinib DMGVH6N Renal cell carcinoma 2C90 Approved [76]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Catenin beta-1 (CTNNB1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cannabidiol DM0659E Dravet syndrome 8A61.11 Approved [77]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [78]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [79]
Quercetin DM3NC4M Obesity 5B81 Approved [80]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [81]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [82]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [83]
Hydroquinone DM6AVR4 Melasma ED60.1 Approved [84]
Testosterone DM7HUNW Hot flushes GA30 Approved [85]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [86]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Mesogenin-1 (MSGN1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [87]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [88]
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tretinoin DM49DUI Acne vulgaris ED80 Approved [87]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [87]
Dolutegravir DMCZGRE Human immunodeficiency virus infection 1C62 Approved [89]
Folic Acid DMEMBJC Colorectal carcinoma Approved [87]
Niclosamide DMJAGXQ Cestodes infection 1F70-1F76 Approved [90]
Dexamethasone DMMWZET Acute adrenal insufficiency Approved [87]
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [91]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [92]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [88]
Milchsaure DM462BT Pruritus EC90 Investigative [93]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Estradiol DMUNTE3 Acne vulgaris ED80 Approved [94]
Sertraline DM0FB1J Coronary heart disease BA80.Z Approved [95]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [96]
Gefitinib DM15F0X Colon adenocarcinoma Approved [97]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [98]
Selenium DM25CGV N. A. N. A. Approved [99]
Ribavirin DMEYLH9 Hepatitis C virus infection 1E51.1 Approved [100]
Trametinib DM2JGQ3 Melanoma 2C30 Approved [101]
Sulindac DM2QHZU Acute myelogenous leukaemia 2A41 Approved [102]
Methotrexate DM2TEOL Anterior urethra cancer Approved [44]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Apolipoprotein A-I (APOA1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [103]
Quercetin DM3NC4M Obesity 5B81 Approved [104]
obeticholic acid DM3Q1SM Primary biliary cholangitis DB96.1 Approved [105]
Glucosamine DM4ZLFD Osteoarthritis FA00-FA05 Approved [106]
Aspirin DM672AH Acute coronary syndrome BA41 Approved [107]
Nevirapine DM6HX9B Human immunodeficiency virus infection 1C62 Approved [108]
Clonidine DM6RZ9Q Attention deficit hyperactivity disorder 6A05.Z Approved [109]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [110]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [111]
Ursodeoxycholic acid DMCUT21 Cholelithiasis DC11 Approved [112]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Alpha-fetoprotein (AFP)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [113]
Methimazole DM25FL8 Hyperthyroidism 5A02 Approved [114]
Simvastatin DM30SGU Arteriosclerosis BD40 Approved [115]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [116]
Isoniazid DM5JVS3 Latent tuberculosis infection Approved [113]
Chlorpromazine DMBGZI3 Acute intermittent hepatic porphyria 5C58.11 Approved [117]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [118]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [48]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [49]
Zoledronate DMIXC7G Adenocarcinoma 2D40 Approved [119]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tretinoin DM49DUI Acne vulgaris ED80 Approved [116]
Polyethylene glycol DM4I1JP Constipation DD91.1 Approved [3]
Thalidomide DM70BU5 Adult T-cell leukemia/lymphoma Approved [3]
Nilotinib DM7HXWT Chronic myelogenous leukaemia 2A20.0 Approved [3]
Ramelteon DM7IW9J Insomnia 7A00-7A0Z Approved [3]
Testosterone enanthate DMB6871 N. A. N. A. Approved [120]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [49]
Temozolomide DMKECZD Adenocarcinoma 2D40 Approved [121]
Abacavir DMMN36E Human immunodeficiency virus infection 1C62 Approved [3]
Phenytoin DMNOKBV Epilepsy 8A60-8A68 Approved [3]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tretinoin DM49DUI Acne vulgaris ED80 Approved [116]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [3]
Panobinostat DM58WKG Chronic graft versus host disease Approved [122]
Thalidomide DM70BU5 Adult T-cell leukemia/lymphoma Approved [3]
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [123]
Nilotinib DM7HXWT Chronic myelogenous leukaemia 2A20.0 Approved [3]
Ramelteon DM7IW9J Insomnia 7A00-7A0Z Approved [3]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [110]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [124]
Dabigatran DMDI6R4 Stroke 8B20 Approved [3]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Homeobox protein CDX-1 (CDX1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [125]
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [126]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [66]
Folic Acid DMEMBJC Colorectal carcinoma Approved [87]
Decitabine DMQL8XJ Acute myelogenous leukaemia 2A41 Approved [127]
Triclosan DMZUR4N Malaria 1F40-1F45 Approved [128]
Resveratrol DM3RWXL Giant cell arteritis 4A44.2 Phase 3 [129]
(+)-JQ1 DM1CZSJ Testicular cancer 2C80 Phase 1 [130]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [88]
bisphenol A DM2ZLD7 Discovery agent N.A. Investigative [131]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Pantothenic acid DM091H2 Vitamin deficiency 5B55-5B71 Approved [132]
Ciprofloxacin XR DM2NLS9 Acute gonococcal cervicitis Approved [133]
Quercetin DM3NC4M Obesity 5B81 Approved [134]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [116]
Panobinostat DM58WKG Chronic graft versus host disease Approved [122]
Chlorpromazine DMBGZI3 Acute intermittent hepatic porphyria 5C58.11 Approved [135]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [136]
Hydroquinone DM6AVR4 Melasma ED60.1 Approved [137]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [66]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [138]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL Anterior urethra cancer Approved [44]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [116]
Panobinostat DM58WKG Chronic graft versus host disease Approved [122]
Thalidomide DM70BU5 Adult T-cell leukemia/lymphoma Approved [3]
Ramelteon DM7IW9J Insomnia 7A00-7A0Z Approved [3]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [66]
Dolutegravir DMCZGRE Human immunodeficiency virus infection 1C62 Approved [89]
Dabigatran DMDI6R4 Stroke 8B20 Approved [3]
Folic Acid DMEMBJC Colorectal carcinoma Approved [139]
Abacavir DMMN36E Human immunodeficiency virus infection 1C62 Approved [3]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Beta-carotene DM0RXBT Vitamin deficiency 5B55-5B71 Approved [140]
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [141]
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [142]
Quercetin DM3NC4M Obesity 5B81 Approved [45]
Troglitazone DM3VFPD Diabetic complication 5A2Y Approved [143]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [140]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [144]
Marinol DM70IK5 Anorexia nervosa cachexia 6B80 Approved [126]
Leflunomide DMR8ONJ Arthritis FA20 Approved [47]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [110]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL Anterior urethra cancer Approved [145]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [146]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [48]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [147]
Temozolomide DMKECZD Adenocarcinoma 2D40 Approved [121]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [148]
Doxorubicin DMVP5YE Acute myelogenous leukaemia 2A41 Approved [149]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [88]
PMID28460551-Compound-2 DM4DOUB N. A. N. A. Patented [150]
bisphenol A DM2ZLD7 Discovery agent N.A. Investigative [131]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [142]
Ciprofloxacin XR DM2NLS9 Acute gonococcal cervicitis Approved [133]
Quercetin DM3NC4M Obesity 5B81 Approved [151]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [152]
Panobinostat DM58WKG Chronic graft versus host disease Approved [122]
Chlorpromazine DMBGZI3 Acute intermittent hepatic porphyria 5C58.11 Approved [135]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [153]
Testosterone DM7HUNW Hot flushes GA30 Approved [154]
Lamotrigine DM8SXYG Bipolar disorder 6A60 Approved [155]
Ibuprofen DM8VCBE Dysmenorrhea GA34.3 Approved [156]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Indian hedgehog protein (IHH)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [131]
Dexamethasone DMMWZET Acute adrenal insufficiency Approved [157]
Fluorouracil DMUM7HZ Adenocarcinoma 2D40 Approved [158]
Urethane DM7NSI0 N. A. N. A. Phase 4 [159]
Resveratrol DM3RWXL Giant cell arteritis 4A44.2 Phase 3 [158]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [88]
PMID28870136-Compound-48 DMPIM9L N. A. N. A. Patented [160]
Deguelin DMXT7WG Esophageal squamous cell carcinoma 2E60.1 Investigative [161]
⏷ Show the Full List of 8 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Hydrogen peroxide DM1NG5W Infectious disease 1A00-CA43.1 Approved [43]
Quercetin DM3NC4M Obesity 5B81 Approved [162]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [116]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [48]
Clorgyline DMCEUJD Parkinson disease 8A00.0 Approved [163]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [66]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [164]
Menadione DMSJDTY Vitamin K deficiency 5B59 Approved [43]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [165]
Progesterone DMUY35B Amenorrhea GA20.0 Approved [166]
⏷ Show the Full List of 10 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Beta-carotene DM0RXBT Vitamin deficiency 5B55-5B71 Approved [140]
Quercetin DM3NC4M Obesity 5B81 Approved [45]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [140]
Testosterone DM7HUNW Hot flushes GA30 Approved [167]
Ciclosporin DMAZJFX Graft-versus-host disease 4B24 Approved [45]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [147]
Vitamin A DMJ2AH4 Night blindness 9D45 Approved [140]
Alitretinoin DMME8LH Kaposi sarcoma 2B57 Approved [140]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [168]
Indomethacin DMSC4A7 Bursitis Approved [169]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Nodal homolog (NODAL)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tretinoin DM49DUI Acne vulgaris ED80 Approved [170]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [171]
Ethanol DMDRQZU Chronic pain MG30 Approved [172]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [173]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [88]
bisphenol A DM2ZLD7 Discovery agent N.A. Investigative [174]
⏷ Show the Full List of 6 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [87]
Cisplatin DMRHGI9 Adenocarcinoma 2D40 Approved [168]
Acetaminophen DMUIE76 Allergic rhinitis CA08.0 Approved [64]
Benzo(a)pyrene DMN7J43 N. A. N. A. Phase 1 [88]
bisphenol A DM2ZLD7 Discovery agent N.A. Investigative [175]
Drug Name Drug ID Indication ICD 11 Highest Status REF
Gefitinib DM15F0X Colon adenocarcinoma Approved [176]
Dactinomycin DM2YGNW Adult kidney Wilms tumor Approved [176]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [176]
Isotretinoin DM4QTBN Acne vulgaris ED80 Approved [176]
Thalidomide DM70BU5 Adult T-cell leukemia/lymphoma Approved [176]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [176]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [155]
Zoledronate DMIXC7G Adenocarcinoma 2D40 Approved [177]
Dasatinib DMJV2EK Blast phase chronic myelogenous leukemia, BCR-ABL1 positive Approved [176]
Ziprasidone DMM58JY Bipolar disorder 6A60 Approved [176]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Affected By Homeobox protein NANOG (NANOG)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fulvestrant DM0YZC6 Breast cancer 2C60-2C65 Approved [178]
Ciprofloxacin XR DM2NLS9 Acute gonococcal cervicitis Approved [133]
Quercetin DM3NC4M Obesity 5B81 Approved [151]
Tretinoin DM49DUI Acne vulgaris ED80 Approved [152]
Panobinostat DM58WKG Chronic graft versus host disease Approved [122]
Chlorpromazine DMBGZI3 Acute intermittent hepatic porphyria 5C58.11 Approved [135]
Arsenic trioxide DM61TA4 Acute lymphoblastic leukaemia 2A85 Approved [153]
Testosterone DM7HUNW Hot flushes GA30 Approved [154]
Valproate DMCFE9I Epilepsy 8A60-8A68 Approved [49]
Ivermectin DMDBX5F Intestinal strongyloidiasis due to nematode parasite 1F6B Approved [138]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Cyclin-dependent kinase 1 (CDK1) TTH6V3D CDK1_HUMAN Inhibitor [2]
Extracellular signal-regulated kinase 2 (ERK2) TT4TQBX MK01_HUMAN Inhibitor [2]
Glycogen synthase kinase-3 alpha (GSK-3A) TTRZQE3 GSK3A_HUMAN Inhibitor [1]
Glycogen synthase kinase-3 beta (GSK-3B) TTRSMW9 GSK3B_HUMAN Inhibitor [2]

Drug Off-Target (DOT)
DOT Name DOT ID UniProt ID Interaction REF
55 kDa erythrocyte membrane protein (MPP1) OTA2ENZQ EM55_HUMAN Gene/Protein Processing [3]
Alpha-fetoprotein (AFP) OT9GG3ZI FETA_HUMAN Gene/Protein Processing [3]
Apolipoprotein A-I (APOA1) OT5THARI APOA1_HUMAN Gene/Protein Processing [3]
Catenin beta-1 (CTNNB1) OTZ932A3 CTNB1_HUMAN Gene/Protein Processing [4]
Cytochrome P450 1A2 (CYP1A2) OTLLBX48 CP1A2_HUMAN Gene/Protein Processing [4]
Cytochrome P450 2E1 (CYP2E1) OTHQ17JG CP2E1_HUMAN Gene/Protein Processing [4]
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Gene/Protein Processing [4]
Fibroblast growth factor 8 (FGF8) OTFU0IUW FGF8_HUMAN Gene/Protein Processing [3]
Glycogen synthase kinase-3 beta (GSK3B) OTL3L14B GSK3B_HUMAN Post-Translational Modifications [5]
Hepatocyte nuclear factor 3-alpha (FOXA1) OTEBY0TD FOXA1_HUMAN Gene/Protein Processing [3]

References

1 Glycogen synthase kinase 3 (GSK-3) inhibitors: a patent update (2014-2015).Expert Opin Ther Pat. 2017 Jun;27(6):657-666.
2 Selective glycogen synthase kinase 3 inhibitors potentiate insulin activation of glucose transport and utilization in vitro and in vivo. Diabetes. 2003 Mar;52(3):588-95.
3 Exposure-based assessment of chemical teratogenicity using morphogenetic aggregates of human embryonic stem cells. Reprod Toxicol. 2020 Jan;91:74-91. doi: 10.1016/j.reprotox.2019.10.004. Epub 2019 Nov 8.
4 Analysis of glycogen synthase kinase inhibitors that regulate cytochrome P450 expression in primary human hepatocytes by activation of beta-catenin, aryl hydrocarbon receptor and pregnane X receptor signaling. Toxicol Sci. 2015 Nov;148(1):261-75.
5 Cytoplasmic aryl hydrocarbon receptor regulates glycogen synthase kinase 3 beta, accelerates vimentin degradation, and suppresses epithelial-mesenchymal transition in non-small cell lung cancer cells. Arch Toxicol. 2017 May;91(5):2165-2178.
6 Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 2009 Jul;8(7):547-66.
7 A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
8 P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models. Mol Cancer Ther. 2007 Mar;6(3):926-34.
9 Small-molecule multi-targeted kinase inhibitor RGB-286638 triggers P53-dependent and -independent anti-multiple myeloma activity through inhibition of transcriptional CDKs. Leukemia. 2013 Dec;27(12):2366-75.
10 A first in man, phase I dose-escalation study of PHA-793887, an inhibitor of multiple cyclin-dependent kinases (CDK2, 1 and 4) reveals unexpected h... Cell Cycle. 2011 Mar 15;10(6):963-70.
11 Cyclin-dependent kinase inhibitors for cancer therapy: a patent review (2009 - 2014).Expert Opin Ther Pat. 2015;25(9):953-70.
12 c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.
13 Discovery of novel CDK1 inhibitors by combining pharmacophore modeling, QSAR analysis and in silico screening followed by in vitro bioassay. Eur J Med Chem. 2010 Sep;45(9):4316-30.
14 DOI: 10.1158/1538-7445.AM2015-4693
15 Clinical pipeline report, company report or official report of HaiHe Biopharma.
16 Clinical pipeline report, company report or official report of Astex Pharmaceuticals.
17 WO patent application no. 2013,1850,32, Nanotherapeutics for drug targeting.
18 ERK Mutations Confer Resistance to Mitogen-Activated Protein Kinase Pathway Inhibitors
19 National Cancer Institute Drug Dictionary (drug name JSI1187).
20 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
21 Corchorusin-D directed apoptosis of K562 cells occurs through activation of mitochondrial and death receptor pathways and suppression of AKT/PKB pathway. Cell Physiol Biochem. 2012;30(4):915-26.
22 How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
23 Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem J. 2000 Oct 1;351(Pt 1):95-105.
24 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
25 The GSK3 kinase inhibitor lithium produces unexpected hyperphosphorylation of -catenin, a GSK3 substrate, in human glioblastoma cells. Biol Open. 2018 Jan 26;7(1):bio030874.
26 Evidence for irreversible inhibition of glycogen synthase kinase-3beta by tideglusib. J Biol Chem. 2012 Jan 6;287(2):893-904.
27 9-ING-41, a small molecule inhibitor of GSK-3beta, potentiates the effects of anticancer therapeutics in bladder cancer. Sci Rep. 2019 Dec 27;9(1):19977.
28 Company report (Neurim Pharmaceuticals)
29 1-Azakenpaullone is a selective inhibitor of glycogen synthase kinase-3 beta. Bioorg Med Chem Lett. 2004 Jan 19;14(2):413-6.
30 Identification of novel scaffold of benzothiazepinones as non-ATP competitive glycogen synthase kinase-3beta inhibitors through virtual screening. Bioorg Med Chem Lett. 2012 Dec 1;22(23):7232-6.
31 Fragment and knowledge-based design of selective GSK-3beta inhibitors using virtual screening models. Eur J Med Chem. 2009 Jun;44(6):2361-71.
32 Challenges and new opportunities in the investigation of new drug therapies to treat frontotemporal dementia. Expert Opin Ther Targets. 2008 Nov;12(11):1367-76.
33 Cannabidiol Modulates the Expression of Alzheimer's Disease-Related Genes in Mesenchymal Stem Cells. Int J Mol Sci. 2016 Dec 23;18(1):26. doi: 10.3390/ijms18010026.
34 Effects and mechanisms of betulinic acid on improving EGFR TKI-resistance of lung cancer cells. Environ Toxicol. 2018 Nov;33(11):1153-1159.
35 The protective effects of liraglutide on AD-like neurodegeneration induced by oxidative stress in human neuroblastoma SH-SY5Y cells. Chem Biol Interact. 2019 Sep 1;310:108688. doi: 10.1016/j.cbi.2019.06.001. Epub 2019 Jun 4.
36 Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
37 Dysregulation of integrin-linked kinase (ILK) signaling in colonic polyposis. Oncogene. 2001 Sep 27;20(43):6250-7. doi: 10.1038/sj.onc.1204791.
38 Differential effects of simvastatin and pravastatin on expression of Alzheimer's disease-related genes in human astrocytes and neuronal cells. J Lipid Res. 2009 Oct;50(10):2095-102. doi: 10.1194/jlr.M900236-JLR200. Epub 2009 May 21.
39 Quercetin potentiates apoptosis by inhibiting nuclear factor-kappaB signaling in H460 lung cancer cells. Biol Pharm Bull. 2013;36(6):944-51. doi: 10.1248/bpb.b12-01004.
40 Suppression of NF-kappaB and GSK-3beta is involved in colon cancer cell growth inhibition by the PPAR agonist troglitazone. Chem Biol Interact. 2010 Oct 6;188(1):75-85. doi: 10.1016/j.cbi.2010.06.001. Epub 2010 Jun 9.
41 Transcriptional and Metabolic Dissection of ATRA-Induced Granulocytic Differentiation in NB4 Acute Promyelocytic Leukemia Cells. Cells. 2020 Nov 5;9(11):2423. doi: 10.3390/cells9112423.
42 NGBR is required to ameliorate type 2 diabetes in mice by enhancing insulin sensitivity. J Biol Chem. 2021 Jan-Jun;296:100624. doi: 10.1016/j.jbc.2021.100624. Epub 2021 Apr 2.
43 Time series analysis of oxidative stress response patterns in HepG2: a toxicogenomics approach. Toxicology. 2013 Apr 5;306:24-34.
44 The contribution of methotrexate exposure and host factors on transcriptional variance in human liver. Toxicol Sci. 2007 Jun;97(2):582-94.
45 Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
46 Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration. Arch Toxicol. 2016 Jan;90(1):159-80.
47 Endoplasmic reticulum stress and MAPK signaling pathway activation underlie leflunomide-induced toxicity in HepG2 Cells. Toxicology. 2017 Dec 1;392:11-21.
48 Integrating multiple omics to unravel mechanisms of Cyclosporin A induced hepatotoxicity in vitro. Toxicol In Vitro. 2015 Apr;29(3):489-501.
49 Human embryonic stem cell-derived test systems for developmental neurotoxicity: a transcriptomics approach. Arch Toxicol. 2013 Jan;87(1):123-43.
50 The aquaglyceroporin AQP9 contributes to the sex-specific effects of in utero arsenic exposure on placental gene expression. Environ Health. 2017 Jun 14;16(1):59. doi: 10.1186/s12940-017-0267-8.
51 Evaluation of developmental toxicity using undifferentiated human embryonic stem cells. J Appl Toxicol. 2015 Feb;35(2):205-18.
52 In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions. Basic Clin Pharmacol Toxicol. 2008 Aug;103(2):157-65.
53 Effects of capsaicin and dihydrocapsaicin on human and rat liver microsomal CYP450 enzyme activities in vitro and in vivo. J Asian Nat Prod Res. 2012;14(4):382-95.
54 Drug interaction study of flavonoids toward CYP3A4 and their quantitative structure activity relationship (QSAR) analysis for predicting potential effects. Toxicol Lett. 2018 Sep 15;294:27-36.
55 Stiripentol. Expert Opin Investig Drugs. 2005 Jul;14(7):905-11.
56 Inhibition of human cytochrome P450 enzymes by 1,4-dihydropyridine calcium antagonists: prediction of in vivo drug-drug interactions. Eur J Clin Pharmacol. 2000 Feb-Mar;55(11-12):843-52.
57 Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor. Drug Metab Dispos. 2003 Nov;31(11):1352-60.
58 Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors. J Med Chem. 2005 Jun 2;48(11):3808-15.
59 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
60 Chemical inhibitors of cytochrome P450 isoforms in human liver microsomes: a re-evaluation of P450 isoform selectivity. Eur J Drug Metab Pharmacokinet. 2011 Mar;36(1):1-16.
61 Inhibition of CYP2E1 catalytic activity in vitro by S-adenosyl-L-methionine. Biochem Pharmacol. 2005 Apr 1;69(7):1081-93.
62 Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins. Cell Biol Toxicol. 2012 Apr;28(2):69-87.
63 An in vitro model of human acute ethanol exposure that incorporates CXCR3- and CXCR4-dependent recruitment of immune cells. Toxicol Sci. 2013 Mar;132(1):131-41.
64 Multiple microRNAs function as self-protective modules in acetaminophen-induced hepatotoxicity in humans. Arch Toxicol. 2018 Feb;92(2):845-858.
65 Proteomic analysis of hepatic effects of phenobarbital in mice with humanized liver. Arch Toxicol. 2022 Oct;96(10):2739-2754. doi: 10.1007/s00204-022-03338-7. Epub 2022 Jul 26.
66 Integrative omics data analyses of repeated dose toxicity of valproic acid in vitro reveal new mechanisms of steatosis induction. Toxicology. 2018 Jan 15;393:160-170.
67 Inhibition of cytochrome P450 enzymes participating in p-nitrophenol hydroxylation by drugs known as CYP2E1 inhibitors. Chem Biol Interact. 2004 Apr 15;147(3):331-40.
68 The relative role of CYP3A4 and CYP3A5 in eplerenone metabolism. Toxicol Lett. 2019 Oct 15;315:9-13.
69 Characterization of the structural determinants required for potent mechanism-based inhibition of human cytochrome P450 1A1 by cannabidiol. Chem Biol Interact. 2014 May 25;215:62-8.
70 Retinoids activate the RXR/SXR-mediated pathway and induce the endogenous CYP3A4 activity in Huh7 human hepatoma cells. Toxicol Sci. 2006 Jul;92(1):51-60.
71 The novel azole R126638 is a selective inhibitor of ergosterol synthesis in Candida albicans, Trichophyton spp., and Microsporum canis. Antimicrob Agents Chemother. 2004 Sep;48(9):3272-8.
72 Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450s. Drug Metab Dispos. 2001 Jan;29(1):30-5.
73 Cetirizine and loratadine-based antihistamines with 5-lipoxygenase inhibitory activity. Bioorg Med Chem Lett. 2004 Nov 15;14(22):5591-4.
74 Mechanism-based inactivation of CYP3A by HIV protease inhibitors. J Pharmacol Exp Ther. 2005 Feb;312(2):583-91.
75 Studies of the toxicological potential of capsinoids, XIII: inhibitory effects of capsaicin and capsinoids on cytochrome P450 3A4 in human liver microsomes. Int J Toxicol. 2010 Mar;29(2 Suppl):22S-6S.
76 Investigation of the effects of axitinib on the pharmacokinetics of loperamide and its main metabolite N-demethylated loperamide in rats by UPLC-MS/MS. Chem Biol Interact. 2019 Sep 1;310:108744. doi: 10.1016/j.cbi.2019.108744. Epub 2019 Jul 9.
77 Inhibition of autophagic flux differently modulates cannabidiol-induced death in 2D and 3D glioblastoma cell cultures. Sci Rep. 2020 Feb 14;10(1):2687. doi: 10.1038/s41598-020-59468-4.
78 Microarray analysis of H2O2-, HNE-, or tBH-treated ARPE-19 cells. Free Radic Biol Med. 2002 Nov 15;33(10):1419-32.
79 Sulindac suppresses beta-catenin expression in human cancer cells. Eur J Pharmacol. 2008 Mar 31;583(1):26-31. doi: 10.1016/j.ejphar.2007.12.034. Epub 2008 Feb 5.
80 Multifaceted preventive effects of single agent quercetin on a human prostate adenocarcinoma cell line (PC-3): implications for nutritional transcriptomics and multi-target therapy. Med Oncol. 2011 Dec;28(4):1395-404. doi: 10.1007/s12032-010-9603-3. Epub 2010 Jul 2.
81 Multifaceted suppression of aggressive behavior of thyroid carcinoma by all-trans retinoic acid induced re-differentiation. Mol Cell Endocrinol. 2012 Jan 2;348(1):260-9. doi: 10.1016/j.mce.2011.09.002. Epub 2011 Sep 6.
82 Arsenic trioxide and 2-methoxyestradiol reduce beta-catenin accumulation after proteasome inhibition and enhance the sensitivity of myeloma cells to Bortezomib. Leuk Res. 2008 Nov;32(11):1674-83. doi: 10.1016/j.leukres.2008.03.039. Epub 2008 May 15.
83 Effect of aspirin on the Wnt/beta-catenin pathway is mediated via protein phosphatase 2A. Oncogene. 2006 Oct 19;25(49):6447-56. doi: 10.1038/sj.onc.1209658. Epub 2006 Jul 31.
84 Benzene metabolite hydroquinone induces apoptosis of bone marrow mononuclear cells through inhibition of -catenin signaling. Toxicol In Vitro. 2018 Feb;46:361-369. doi: 10.1016/j.tiv.2017.08.018. Epub 2017 Sep 5.
85 Anti-androgen 2-hydroxyflutamide modulates cadherin, catenin and androgen receptor phosphorylation in androgen-sensitive LNCaP and androgen-independent PC3 prostate cancer cell lines acting via PI3K/Akt and MAPK/ERK1/2 pathways. Toxicol In Vitro. 2017 Apr;40:324-335. doi: 10.1016/j.tiv.2017.01.019. Epub 2017 Feb 2.
86 Anthelmintic Niclosamide Disrupts the Interplay of p65 and FOXM1/-catenin and Eradicates Leukemia Stem Cells in Chronic Myelogenous Leukemia. Clin Cancer Res. 2017 Feb 1;23(3):789-803. doi: 10.1158/1078-0432.CCR-16-0226. Epub 2016 Aug 4.
87 Neuronal and cardiac toxicity of pharmacological compounds identified through transcriptomic analysis of human pluripotent stem cell-derived embryoid bodies. Toxicol Appl Pharmacol. 2021 Dec 15;433:115792. doi: 10.1016/j.taap.2021.115792. Epub 2021 Nov 3.
88 Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
89 Dolutegravir Impairs Stem Cell-Based 3D Morphogenesis Models in a Manner Dependent on Dose and Timing of Exposure: An Implication for Its Developmental Toxicity. Toxicol Sci. 2021 Nov 24;184(2):191-203. doi: 10.1093/toxsci/kfab112.
90 Mitochondrial Uncoupling Induces Epigenome Remodeling and Promotes Differentiation in Neuroblastoma. Cancer Res. 2023 Jan 18;83(2):181-194. doi: 10.1158/0008-5472.CAN-22-1029.
91 17-Estradiol Activates HSF1 via MAPK Signaling in ER-Positive Breast Cancer Cells. Cancers (Basel). 2019 Oct 11;11(10):1533. doi: 10.3390/cancers11101533.
92 The NRF2-mediated oxidative stress response pathway is associated with tumor cell resistance to arsenic trioxide across the NCI-60 panel. BMC Med Genomics. 2010 Aug 13;3:37. doi: 10.1186/1755-8794-3-37.
93 Transcriptional profiling of lactic acid treated reconstructed human epidermis reveals pathways underlying stinging and itch. Toxicol In Vitro. 2019 Jun;57:164-173.
94 Acetaminophen-induced proliferation of estrogen-responsive breast cancer cells is associated with increases in c-myc RNA expression and NF-kappaB activity. Toxicol Sci. 2002 Apr;66(2):233-43. doi: 10.1093/toxsci/66.2.233.
95 Sertraline induces endoplasmic reticulum stress in hepatic cells. Toxicology. 2014 Aug 1;322:78-88. doi: 10.1016/j.tox.2014.05.007. Epub 2014 May 24.
96 Estrogen regulation in human breast cancer cells of new downstream gene targets involved in estrogen metabolism, cell proliferation and cell transformation. J Mol Endocrinol. 2004 Apr;32(2):397-414.
97 ZD1839 induces p15INK4b and causes G1 arrest by inhibiting the mitogen-activated protein kinase/extracellular signal-regulated kinase pathway. Mol Cancer Ther. 2007 May;6(5):1579-87. doi: 10.1158/1535-7163.MCT-06-0814.
98 Arsenic suppresses gene expression in promyelocytic leukemia cells partly through Sp1 oxidation. Blood. 2005 Jul 1;106(1):304-10.
99 Selenite and selenomethionine promote HL-60 cell cycle progression. J Nutr. 2002 Apr;132(4):674-9. doi: 10.1093/jn/132.4.674.
100 Ribavirin augments doxorubicin's efficacy in human hepatocellular carcinoma through inhibiting doxorubicin-induced eIF4E activation. J Biochem Mol Toxicol. 2018 Jan;32(1). doi: 10.1002/jbt.22007. Epub 2017 Nov 7.
101 Combination small molecule MEK and PI3K inhibition enhances uveal melanoma cell death in a mutant GNAQ- and GNA11-dependent manner. Clin Cancer Res. 2012 Aug 15;18(16):4345-55. doi: 10.1158/1078-0432.CCR-11-3227. Epub 2012 Jun 25.
102 Novel detection and differential utilization of a c-myc transcriptional block in colon cancer chemoprevention. Cancer Res. 2002 Nov 1;62(21):6006-10.
103 Simvastatin, an HMG-CoA reductase inhibitor, induces the synthesis and secretion of apolipoprotein AI in HepG2 cells and primary hamster hepatocytes. Atherosclerosis. 2002 Jul;163(1):59-68. doi: 10.1016/s0021-9150(01)00754-7.
104 Quercetin represses apolipoprotein B expression by inhibiting the transcriptional activity of C/EBP. PLoS One. 2015 Apr 15;10(4):e0121784. doi: 10.1371/journal.pone.0121784. eCollection 2015.
105 Pharmacotoxicology of clinically-relevant concentrations of obeticholic acid in an organotypic human hepatocyte system. Toxicol In Vitro. 2017 Mar;39:93-103.
106 Effect of glucosamine on apolipoprotein AI mRNA stabilization and expression in HepG2 cells. Metabolism. 2004 Jun;53(6):766-71. doi: 10.1016/j.metabol.2003.11.027.
107 Induction of paraoxonase 1 and apolipoprotein A-I gene expression by aspirin. J Lipid Res. 2008 Oct;49(10):2142-8.
108 Nevirapine increases high-density lipoprotein cholesterol concentration by stimulation of apolipoprotein A-I production. Arterioscler Thromb Vasc Biol. 2009 Sep;29(9):1336-41. doi: 10.1161/ATVBAHA.109.192088. Epub 2009 Aug 10.
109 The effects of clonidine hydrochloride versus atenolol monotherapy on serum lipids, lipid subfractions, and apolipoproteins in mild hypertension. Am Heart J. 1990 Jul;120(1):172-9. doi: 10.1016/0002-8703(90)90175-w.
110 Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 2010 May;115(1):66-79.
111 Integrated 'omics analysis reveals new drug-induced mitochondrial perturbations in human hepatocytes. Toxicol Lett. 2018 Jun 1;289:1-13.
112 Hepatic apolipoprotein A-I gene expression in patients with cholesterol gallstones treated with ursodeoxycholic acid. Ann Hepatol. 2002 Apr-Jun;1(2):85-9.
113 Comparison of base-line and chemical-induced transcriptomic responses in HepaRG and RPTEC/TERT1 cells using TempO-Seq. Arch Toxicol. 2018 Aug;92(8):2517-2531.
114 Low-expressional IGF1 mediated methimazole-induced liver developmental toxicity in fetal mice. Toxicology. 2018 Sep 1;408:70-79. doi: 10.1016/j.tox.2018.07.004. Epub 2018 Jul 7.
115 Effect of simvastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, on alpha-fetoprotein gene expression through interaction with the ras-mediated pathway. J Hepatol. 1999 May;30(5):904-10. doi: 10.1016/s0168-8278(99)80146-9.
116 Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
117 Effects of chlorpromazine with and without UV irradiation on gene expression of HepG2 cells. Mutat Res. 2005 Aug 4;575(1-2):47-60. doi: 10.1016/j.mrfmmm.2005.03.002. Epub 2005 Apr 26.
118 Expression of AFP and STAT3 is involved in arsenic trioxide-induced apoptosis and inhibition of proliferation in AFP-producing gastric cancer cells. PLoS One. 2013;8(1):e54774. doi: 10.1371/journal.pone.0054774. Epub 2013 Jan 30.
119 Zoledronate dysregulates fatty acid metabolism in renal tubular epithelial cells to induce nephrotoxicity. Arch Toxicol. 2018 Jan;92(1):469-485.
120 Transcriptional profiling of testosterone-regulated genes in the skeletal muscle of human immunodeficiency virus-infected men experiencing weight loss. J Clin Endocrinol Metab. 2007 Jul;92(7):2793-802. doi: 10.1210/jc.2006-2722. Epub 2007 Apr 17.
121 Temozolomide induces activation of Wnt/-catenin signaling in glioma cells via PI3K/Akt pathway: implications in glioma therapy. Cell Biol Toxicol. 2020 Jun;36(3):273-278. doi: 10.1007/s10565-019-09502-7. Epub 2019 Nov 22.
122 A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
123 hiPSC-Based Model of Prenatal Exposure to Cannabinoids: Effect on Neuronal Differentiation. Front Mol Neurosci. 2020 Jul 6;13:119. doi: 10.3389/fnmol.2020.00119. eCollection 2020.
124 Epigenetic changes and disturbed neural development in a human embryonic stem cell-based model relating to the fetal valproate syndrome. Hum Mol Genet. 2012 Sep 15;21(18):4104-14. doi: 10.1093/hmg/dds239. Epub 2012 Jun 20.
125 Effect of chronic exposure to inorganic arsenic on intestinal cells. J Appl Toxicol. 2019 Jun;39(6):899-907. doi: 10.1002/jat.3778. Epub 2019 Feb 12.
126 THC exposure of human iPSC neurons impacts genes associated with neuropsychiatric disorders. Transl Psychiatry. 2018 Apr 25;8(1):89. doi: 10.1038/s41398-018-0137-3.
127 Induction of intestinalization in human esophageal keratinocytes is a multistep process. Carcinogenesis. 2009 Jan;30(1):122-30. doi: 10.1093/carcin/bgn227. Epub 2008 Oct 8.
128 Transcriptome and DNA methylome dynamics during triclosan-induced cardiomyocyte differentiation toxicity. Stem Cells Int. 2018 Oct 29;2018:8608327.
129 Differential regulation of proliferation, cell cycle control and gene expression in cultured human aortic and pulmonary artery endothelial cells by resveratrol. Int J Mol Med. 2010 Nov;26(5):743-9.
130 CCAT1 is an enhancer-templated RNA that predicts BET sensitivity in colorectal cancer. J Clin Invest. 2016 Feb;126(2):639-52.
131 DNA methylome-wide alterations associated with estrogen receptor-dependent effects of bisphenols in breast cancer. Clin Epigenetics. 2019 Oct 10;11(1):138. doi: 10.1186/s13148-019-0725-y.
132 Calcium pantothenate modulates gene expression in proliferating human dermal fibroblasts. Exp Dermatol. 2009 Nov;18(11):969-78. doi: 10.1111/j.1600-0625.2009.00884.x. Epub 2009 Apr 8.
133 Ciprofloxacin mediates cancer stem cell phenotypes in lung cancer cells through caveolin-1-dependent mechanism. Chem Biol Interact. 2016 Apr 25;250:1-11.
134 Apigenin Inhibits Cancer Stem Cell-Like Phenotypes in Human Glioblastoma Cells via Suppression of c-Met Signaling. Phytother Res. 2016 Nov;30(11):1833-1840. doi: 10.1002/ptr.5689. Epub 2016 Jul 29.
135 The antipsychotic chlorpromazine suppresses YAP signaling, stemness properties, and drug resistance in breast cancer cells. Chem Biol Interact. 2019 Apr 1;302:28-35. doi: 10.1016/j.cbi.2019.01.033. Epub 2019 Jan 28.
136 Arsenic trioxide inhibits Hedgehog, Notch and stem cell properties in glioblastoma neurospheres. Acta Neuropathol Commun. 2014 Mar 31;2:31. doi: 10.1186/2051-5960-2-31.
137 Keratinocyte-derived IL-36gama plays a role in hydroquinone-induced chemical leukoderma through inhibition of melanogenesis in human epidermal melanocytes. Arch Toxicol. 2019 Aug;93(8):2307-2320.
138 Ivermectin as an inhibitor of cancer stem?like cells. Mol Med Rep. 2018 Feb;17(2):3397-3403. doi: 10.3892/mmr.2017.8231. Epub 2017 Dec 8.
139 Folic acid supplementation dysregulates gene expression in lymphoblastoid cells--implications in nutrition. Biochem Biophys Res Commun. 2011 Sep 9;412(4):688-92. doi: 10.1016/j.bbrc.2011.08.027. Epub 2011 Aug 16.
140 Beta-carotene and apocarotenals promote retinoid signaling in BEAS-2B human bronchioepithelial cells. Arch Biochem Biophys. 2006 Nov 1;455(1):48-60.
141 Arsenite and cadmium promote the development of mammary tumors. Carcinogenesis. 2020 Jul 14;41(7):1005-1014. doi: 10.1093/carcin/bgz176.
142 Global gene expression analysis reveals differences in cellular responses to hydroxyl- and superoxide anion radical-induced oxidative stress in caco-2 cells. Toxicol Sci. 2010 Apr;114(2):193-203. doi: 10.1093/toxsci/kfp309. Epub 2009 Dec 31.
143 Activation of PPAR and inhibition of cell proliferation reduces key proteins associated with the basal subtype of bladder cancer in As3+-transformed UROtsa cells. PLoS One. 2020 Aug 21;15(8):e0237976. doi: 10.1371/journal.pone.0237976. eCollection 2020.
144 Analysis of the transcriptional regulation of cancer-related genes by aberrant DNA methylation of the cis-regulation sites in the promoter region during hepatocyte carcinogenesis caused by arsenic. Oncotarget. 2015 Aug 28;6(25):21493-506. doi: 10.18632/oncotarget.4085.
145 Methotrexate modulates folate phenotype and inflammatory profile in EA.hy 926 cells. Eur J Pharmacol. 2014 Jun 5;732:60-7.
146 Phenotypic characterization of retinoic acid differentiated SH-SY5Y cells by transcriptional profiling. PLoS One. 2013 May 28;8(5):e63862.
147 Design principles of concentration-dependent transcriptome deviations in drug-exposed differentiating stem cells. Chem Res Toxicol. 2014 Mar 17;27(3):408-20.
148 Predictive toxicology using systemic biology and liver microfluidic "on chip" approaches: application to acetaminophen injury. Toxicol Appl Pharmacol. 2012 Mar 15;259(3):270-80.
149 Bringing in vitro analysis closer to in vivo: studying doxorubicin toxicity and associated mechanisms in 3D human microtissues with PBPK-based dose modelling. Toxicol Lett. 2018 Sep 15;294:184-192.
150 Cell-based two-dimensional morphological assessment system to predict cancer drug-induced cardiotoxicity using human induced pluripotent stem cell-derived cardiomyocytes. Toxicol Appl Pharmacol. 2019 Nov 15;383:114761. doi: 10.1016/j.taap.2019.114761. Epub 2019 Sep 15.
151 Quercetin in elimination of tumor initiating stem-like and mesenchymal transformation property in head and neck cancer. Head Neck. 2013 Mar;35(3):413-9. doi: 10.1002/hed.22982. Epub 2012 Mar 16.
152 Retinoic acid represses a cassette of candidate pluripotency chromosome 12p genes during induced loss of human embryonal carcinoma tumorigenicity. Biochim Biophys Acta. 2005 Oct 15;1731(1):48-56. doi: 10.1016/j.bbaexp.2005.08.006. Epub 2005 Sep 1.
153 Arsenic trioxide induces differentiation of cancer stem cells in hepatocellular carcinoma through inhibition of LIF/JAK1/STAT3 and NF-kB signaling pathways synergistically. Clin Transl Med. 2021 Feb;11(2):e335. doi: 10.1002/ctm2.335.
154 Altered expression of genes identified in rats with prostatic chronic inflammation in a prostate spheroid model treated by estradiol/testosterone. J Toxicol Sci. 2021;46(11):515-523. doi: 10.2131/jts.46.515.
155 Antiepileptic drugs are endocrine disruptors for the human fetal testis ex vivo. Toxicol Sci. 2023 Sep 28;195(2):169-183. doi: 10.1093/toxsci/kfad076.
156 Effects of Exposure to Acetaminophen and Ibuprofen on Fetal Germ Cell Development in Both Sexes in Rodent and Human Using Multiple Experimental Systems. Environ Health Perspect. 2018 Apr 16;126(4):047006. doi: 10.1289/EHP2307.
157 Parathyroid hormone 1-34 reduces dexamethasone-induced terminal differentiation in human articular chondrocytes. Toxicology. 2016 Aug 10;368-369:116-128.
158 Effect of resveratrol on proliferation and apoptosis of human pancreatic cancer MIA PaCa-2 cells may?involve inhibition of the Hedgehog signaling pathway. Mol Med Rep. 2014 Nov;10(5):2563-7. doi: 10.3892/mmr.2014.2511. Epub 2014 Aug 21.
159 Ethyl carbamate induces cell death through its effects on multiple metabolic pathways. Chem Biol Interact. 2017 Nov 1;277:21-32.
160 Global expression profiling of theophylline response genes in macrophages: evidence of airway anti-inflammatory regulation. Respir Res. 2005 Aug 8;6(1):89. doi: 10.1186/1465-9921-6-89.
161 Deguelin inhibits growth of breast cancer cells by modulating the expression of key members of the Wnt signaling pathway. Cancer Prev Res (Phila). 2009 Nov;2(11):942-50. doi: 10.1158/1940-6207.CAPR-08-0232. Epub 2009 Oct 27.
162 Quantitative phosphoproteomics reveal cellular responses from caffeine, coumarin and quercetin in treated HepG2 cells. Toxicol Appl Pharmacol. 2022 Aug 15;449:116110. doi: 10.1016/j.taap.2022.116110. Epub 2022 Jun 7.
163 Anti-oncogenic and pro-differentiation effects of clorgyline, a monoamine oxidase A inhibitor, on high grade prostate cancer cells. BMC Med Genomics. 2009 Aug 20;2:55. doi: 10.1186/1755-8794-2-55.
164 Low doses of cisplatin induce gene alterations, cell cycle arrest, and apoptosis in human promyelocytic leukemia cells. Biomark Insights. 2016 Aug 24;11:113-21.
165 Gene expression analysis of precision-cut human liver slices indicates stable expression of ADME-Tox related genes. Toxicol Appl Pharmacol. 2011 May 15;253(1):57-69.
166 The human myometrium differentially expresses mTOR signalling components before and during pregnancy: evidence for regulation by progesterone. J Steroid Biochem Mol Biol. 2014 Jan;139:166-72. doi: 10.1016/j.jsbmb.2013.02.017. Epub 2013 Mar 26.
167 The exosome-like vesicles derived from androgen exposed-prostate stromal cells promote epithelial cells proliferation and epithelial-mesenchymal transition. Toxicol Appl Pharmacol. 2021 Jan 15;411:115384. doi: 10.1016/j.taap.2020.115384. Epub 2020 Dec 25.
168 Activation of AIFM2 enhances apoptosis of human lung cancer cells undergoing toxicological stress. Toxicol Lett. 2016 Sep 6;258:227-236.
169 Mechanisms of indomethacin-induced alterations in the choline phospholipid metabolism of breast cancer cells. Neoplasia. 2006 Sep;8(9):758-71.
170 Molecular characterization of a toxicological tipping point during human stem cell differentiation. Reprod Toxicol. 2020 Jan;91:1-13. doi: 10.1016/j.reprotox.2019.10.001. Epub 2019 Oct 7.
171 Gene Expression Regulation and Pathway Analysis After Valproic Acid and Carbamazepine Exposure in a Human Embryonic Stem Cell-Based Neurodevelopmental Toxicity Assay. Toxicol Sci. 2015 Aug;146(2):311-20. doi: 10.1093/toxsci/kfv094. Epub 2015 May 15.
172 Chronic ethanol exposure increases goosecoid (GSC) expression in human embryonic carcinoma cell differentiation. J Appl Toxicol. 2014 Jan;34(1):66-75.
173 MicroRNA 376c enhances ovarian cancer cell survival by targeting activin receptor-like kinase 7: implications for chemoresistance. J Cell Sci. 2011 Feb 1;124(Pt 3):359-68. doi: 10.1242/jcs.072223. Epub 2011 Jan 11.
174 Unique bisphenol A transcriptome in prostate cancer: novel effects on ERbeta expression that correspond to androgen receptor mutation status. Environ Health Perspect. 2007 Nov;115(11):1646-53. doi: 10.1289/ehp.10283.
175 Bisphenol A induces DSB-ATM-p53 signaling leading to cell cycle arrest, senescence, autophagy, stress response, and estrogen release in human fetal lung fibroblasts. Arch Toxicol. 2018 Apr;92(4):1453-1469.
176 A high-throughput screen for teratogens using human pluripotent stem cells. Toxicol Sci. 2014 Jan;137(1):76-90. doi: 10.1093/toxsci/kft239. Epub 2013 Oct 23.
177 Interleukin-19 as a translational indicator of renal injury. Arch Toxicol. 2015 Jan;89(1):101-6.
178 Methylparaben stimulates tumor initiating cells in ER+ breast cancer models. J Appl Toxicol. 2017 Apr;37(4):417-425. doi: 10.1002/jat.3374. Epub 2016 Sep 1.